TWST - NASDAQ
Twist Bioscience Corporation
$72.33
+6.8%Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research, Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. Twist Bioscience Corporation was incorporated in 2013 and is headquartered in South San Francisco, California.
At a Glance
Live Snapshottwst
Gross Profit
Last Annual Value
191.00M
3-Year CAGR
31%
5-Year CAGR
46%
10-Year CAGR
40%
Twist Bioscience Corporation Competitors Analysis of Gross Profit
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Twist Bioscience Corporation NASDAQ:TWST | 191.00M | 28.6% | 29.9% | N/A | |
 uniQure N.V. NASDAQ:QURE | 14.41M | 86.7% | -50.8% | N/A | |
 Structure Therapeutics Inc. NASDAQ:GPCR | -3.90M | N/A | N/A | N/A | |
 QuidelOrtho Corporation NASDAQ:QDEL | 1.27B | -5.2% | -0.1% | N/A | |
 Clover Health Investments, Corp. NASDAQ:CLOV | 355.88M | 11.6% | N/A | N/A | |
 PROCEPT BioRobotics Corporation NASDAQ:PRCT | 196.23M | 40.3% | 65.4% | N/A | |
 Edgewise Therapeutics, Inc. NASDAQ:EWTX | -2.27M | N/A | N/A | N/A | |
 Viridian Therapeutics, Inc. NASDAQ:VRDN | 69.69M | 505.4% | 88.1% | 56.5% | |
 Guardian Pharmacy Services, Inc. NYSE:GRDN | 282.04M | 10.6% | 11.8% | N/A |
Twist Bioscience Corporation Fair Value Envelope
Related Guides
Continue your TWST research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.